Merrimack Pharmaceuticals, Inc. (MACK)

[Mitshu35]

Nice write up on MACK by Bret Jensen on SA today:

So what "Tier 3" stocks do I like as standalone entities but see as logical acquisition targets? Here are two names that should be on your shopping list.

Merrimack Pharmaceuticals (NASDAQ:MACK) - The company has one product "Onivyde" recently approved on the market for a type of pancreatic cancer as well as in late stage trials for other indications. Onivyde also just got the "thumbs up" from The European Medicines Agency's Committee for Medicinal Products for Human Use {CHMP}. It will be marketed there by Shire (NASDAQ:SHPG) which is Merrimack's marketing and distribution partner outside the United States.

Another compound in Merrimack's pipeline (seribantumab) recently received Fast Track review for the treatment of patients with heregulin-positive, locally advanced or metastatic non-small cell lung cancer. Merrimack has a market capitalization of under $700 million, a stock price under $6.00 a share and has a median price target by the analysts that cover it of $12 according to Tipranks. For a more detailed analysis of why I like Merrimack, click here.

http://seekingalpha.com/article/3994487-small-biotech-moving-risk-curve?v=1470150549&commenter=1&comments=show

And his previous write up:

http://seekingalpha.com/article/3961298-biotech-forum-daily-digest-mercks-pyrrhic-victory-gilead-amgens-patent-win-spotlight